ChromaTan Receives a $2M Phase IIB NIH Grant

ChromaTan, a Lower Gwynedd, PA-based bioprocessing and biotools biomanufacturing technology platform development company, received a NIH IIB grant of $2M from the National Institute of General Medical Sciences

The company intends to use the funds for the development and integration of its novel BioRMB™ single-use, column-free, steady-state continuous counter-current elution technology for manufacturing AAVs.

The project aims to provide an AAV purification process trains for at least 2 AAV serotypes sourced from Chromatan’s commercial partners for both capture and polishing (empty/full separation) as well as scale the BioRMB™ platform to both pilot and large-scale cGMP production.

ChromaTan is a bioprocessing and biotools company that has created a novel purification system called BioRMB™ (formerly known as Continuous Countercurrent Tangential Chromatography or CCTC). The platform has been launched in 2023, and has demonstrated improvements in productivity, product recovery and product quality for multiple types of biologics including gene therapies, mRNA and monoclonal antibodies.